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Influenza is a highly infectious airborne disease with an impor-
tant epidemiological and societal burden; annual epidemics and 
pandemics have occurred since ancient times, causing tens of mil-
lions of deaths. A hundred years after this virus was first isolated, 
influenza vaccines are an important influenza prevention strategy 
and the preparations used display good safety and tolerability 
profiles. Innovative tools, such as recombinant technologies and 
intra-dermal devices, are currently being investigated in order to 
improve the immunological response. The recurring mutations of 
influenza strains has prompted the recent introduction of a quad-
rivalent inactivated vaccine. In the near future, scientific research 
will strive to produce a long-lasting universal vaccine containing 
an antigen that will offer protection against all influenza virus 
strains.
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Summary
Introduction
Influenza viruses are negative-sense, single-stranded 
RNA viruses belonging to the Orthomyxoviridae family, 
together with Isavirus, Thogotovirus and Quaranjavi-
rus. Three types of influenza viruses, namely influenza 
A, B and C, are capable of determining epidemics and 
pandemics in humans, with influenza A being the most 
common circulating type and causing significant illness, 
being  most prone to antigenic shifts and the more likely 
type to lead to a pandemic [1, 2]. Recently, a new genus 
(termed influenza virus D) has been discovered in pigs 
and cattle with influenza-like illness syndrome in the 
United States [3, 4] and in Europe [5].
Influenza is a highly infectious airborne disease that 
affects a significant percentage of the world’s popula-
tion; local annual epidemics and pandemics have oc-
curred since ancient times, causing tens of millions of 
deaths [6].
The aim of this mini-review is to provide a brief over-
view of the history and evolution of influenza and influ-
enza control using vaccines.
A history of influenza: from the classical 
period to the nineteenth century
In 412 BC, in the “Book of Epidemics”, Hippocrates de-
scribed a putative influenza-like illness syndrome called 
“fever of Perinthus” or “cough of Perinthus” [7]. While 
some scholars claim that this is probably the first histori-
cal description of influenza (a winter and a spring epi-
demic of an upper respiratory tract infection occurring 
regularly every year at Perinthus, a port-town in Mar-
maraereglisi, a northern part of Greece, now Turkey), 
others, including the notable 19th-century editor of Hip-
pocrates, Émile Littré (1801-1881), think that a diagno-
sis of diphtheria would better fit the description of com-
plications (pneumonia, fits of coughing and wheezing, 
angina and paralysis of soft palate and limbs). On the 
other hand, symptoms such as disturbed vision and night 
blindness suggest a combination of diseases, including 
deficiency syndromes (e.g. vitamin A deficiency) [8]. In 
the years 1173 and 1500, two other influenza outbreaks 
were described, though in scant detail [9-11]. The name 
“influenza” originated in the 15th century in Italy, from 
an epidemic attributed to the “influence of the stars”, 
which, according to Ginctrac, raged across Europe and 
perhaps in Asia and Africa [12]. 
It seems that influenza also reached the Americas. 
Scholars and historians debate whether influenza was 
already present in the New World or whether it was car-
ried by contaminated pigs transported on ships. Some 
Aztec texts speak of a “pestilential catarrh” outbreak in 
1450-1456 in an area now corresponding to Mexico, but 
these manuscripts are difficult to interpret correctly and 
this hypothesis seems controversial [13].
The first reliable documents regarding influenza-like ill-
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ness syndrome date from 1510, when the virus spread from 
Africa to Europe. The first pandemic, or worldwide epi-
demic, occurred in 1557, though some scholars deny that 
it really was an outbreak of influenza. The first pandemic/
worldwide epidemic that undoubtedly fits the description 
of influenza appeared in 1580, beginning in Asia and Rus-
sia and spreading to Europe via Asia Minor and North-West 
Africa. In Rome, it caused the death of over 8,000 people, 
while in Spain it decimated the populations of entire cities. 
Subsequently, it also affected the Americas [14].
Over the centuries, other pandemics were described 
worldwide. From 1404 to the middle of the 19th century, 
31 influenza epidemics were recorded, including eight 
large-scale pandemics. Subsequently, others appeared, 
including three in the 20th century  [14]. Some of the 
most notable outbreaks occurred in 1729, in 1781-1782 
(a pandemic spreading from China to Russia, Europe and 
North America), in 1830-1833 (a pandemic which again 
spread from China to India, the Philippines, Indonesia, 
Russia, Europe and North America), in 1847-1848, and 
in 1898-1900 (spreading from Europe to India, Austra-
lia, and North and South America) [14].
One of the most devastating was the pandemic of “Span-
ish” influenza in 1918–1919, which caused an estimated 
21 million deaths worldwide and was defined by Waring 
as “the greatest medical holocaust in history” [14, 15]. 
At the end of the 19th century, the etiology of this disease 
had yet not been well clarified; it was believed that the 
disease, termed “winter catarrh”, was caused by bacte-
ria (the so-called bacterial hypothesis), such as pneu-
mococcus, streptococcus or Haemophilus influenzae. 
This latter was also named Bacillus influenzae or Pfei-
ffer’s bacillus, after Richard Pfeiffer (1858-1945), who 
described it during the 1889-1892 influenza epidemic. 
This bacillus had already been discovered by the Pol-
ish microbiologist Bujwid Odo Feliks Kazimierz (1857-
1942) in biopsy material a year earlier [16]. 
In the same period, the French microbiologists Charles 
Nicolle (1866-1936), Charles Lébally and René Dujar-
ric de la Rivière (1885-1969) of the Pasteur Institute 
showed that the flu pathogen could pass through a fine 
filter. However, despite their brilliant experiments, the 
viral hypothesis continued to be neglected until the virus 
was isolated [16, 17].
In 1889, some Spanish doctors believed that influenza 
was a variant of dengue fever, whilst others attributed 
influenza outbreaks to a variety of causes including can-
non fire on the western front, the building of the Madrid 
underground, air pollution, sunspots, or the spread of the 
habit of smoking poor-quality tobacco [18].
The thirties: virus isolation and the first 
experimental vaccines
During the 1918-1919 pandemic, some scientists began 
to suspect that bacteria were not the real agent of in-
fluenza disease. One of these was the scholar Richard 
Edwin Shope (1901-1966), who deeply investigated 
swine flu in 1920. However, it was only in 1932-1933 
that the English scientists Wilson Smith (1897-1965), 
Sir Christopher Andrewes (1896-1988) and Sir Patrick 
Laidlaw (1881-1940), working at the Medical Research 
Council at Mill Hill, first isolated the influenza A vi-
rus from nasal secretions of infected patients, thereby 
demonstrating the intranasal human transmission of this 
virus [19, 20]. A few years later, the American virologist 
and epidemiologist Thomas Francis Junior (1900-1969) 
and Smith, in England, were able to transmit the virus to 
mice [21]. Subsequently, in 1935, Sir Frank Macfarlane 
Burnet (1899-1985) and Smith separately discovered 
that the flu virus could be grown on the chorio-allantoid 
membrane of embryonated hens’ eggs [22], and in 1936 
the first neutralized antibodies generated by infection by 
human influenza virus were isolated [23]. 
In the next five years, important developments took 
place: the demonstration that the virus inactivated by 
formalin was immunogenic in humans, purification of 
the virus by means of high-speed centrifugation, and 
the discovery that the influenza virus grew easily in fer-
tilized hen eggs, a procedure that is still used today to 
manufacture most influenza vaccines [23]. 
The first clinical trials of influenza vaccines were con-
ducted in the mid-1930s [24, 25]. 
A study by Smith, Andrewes and Stuart-Harris was con-
ducted among military forces in England in 1937 using a 
subcutaneous vaccination with an inactivated strain iso-
lated from a mouse lung [25].
In 1938, Francis, together with Jonas Edward Salk 
(1914-1995), managed to protect USA military forces. 
Salk would subsequently use this successful experience 
to develop an effective polio vaccine in 1952 [26, 27].
The forties: inactivated influenza 
vaccines
Influenza vaccination had two main objectives: (i) to 
protect against disease, and (ii) to achieve a high vacci-
nation rate in order to ensure protection in unvaccinated 
people. The first vaccine was an inactivated, monovalent 
preparation which only contained a subtype of the influ-
enza A virus [26, 27]. 
In December 1942, large studies were begun to be conduct-
ed on the first influenza virus vaccines; these provided the 
first official proof that inactivated influenza vaccines could 
yield effective protection against flu epidemics [28].
The efficacy and safety of inactivated vaccines were 
first studied between 1942 and 1945; in the meantime, 
a new strain of flu virus was discovered, the influenza 
virus type B, which is the main cause of seasonal epi-
demics, as was the phenomenon of so-called “influenza 
mismatch”. Influenza mismatch is caused by major and 
minor mutations of circulating viruses. As a result, the 
virus contained in the vaccine does not match the circu-
lating strain, determining a reduction in the effectiveness 
of subtype A influenza vaccines. 
A new route of influenza immunization was tested in 
December 1942, with the subcutaneous inactivated bi-
valent vaccine containing viruses of type A and type B. 
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The following years, the first bivalent vaccine was li-
censed in the United States and became available for use 
in the general population [29, 30]. 
The fifties: influenza mismatch  
and influenza surveillance
The first system for the surveillance of circulating influenza 
virus strains in several countries worldwide was created in 
1952 by the World Health Organization (WHO) in order to 
monitor the various virus mismatches reported. This impor-
tant innovative tool enabled the composition of seasonal in-
fluenza vaccines to be determined on the basis of the epide-
miology of influenza in the previous season [31]. In 1946, 
as a result of viral mutation, a new variant of influenza A 
(H1N1), A/FM/1/47, appeared in Australia. This gave rise 
to a new influenza subtype, the H2N2 strain, which caused 
the pandemic known as Asian flu [32]. 
The following year, the US Commission on Influenza 
recommended that a representative of this strain be in-
cluded in subsequent vaccines.
The emergence of an HA subtype different from those 
circulating in previous seasons determined the need for 
pandemic influenza vaccines [31]. 
The sixties: split vaccines
New inactivated compounds were tested for safety and ef-
ficacy during seasonal epidemics in the 1960s, in particu-
lar two new formulations were created: split and subunit 
vaccines. The 1968 pandemic led to the development of 
trivalent inactivated vaccines (TIVs) against influenza vi-
ruses; moreover the development of new split or subunit 
vaccines led to a decrease of adverse reactions in chil-
dren. These vaccines were split using ether and/or deter-
gent, and haemagglutinin and neuraminidase were, in the 
case of subunit vaccines, purified and enriched [ 33]. 
In the same period, the first flu vaccines were licensed 
in Europe, while in the US annual influenza vaccination 
was recommended for individuals at major risk of influ-
enza complications.
In 1968, the new virus strain H3N2 (Hong Kong) ap-
peared, completely replacing the previous type A strain 
(H2N2, or Asian influenza), and led to another global 
pandemic with high morbidity and mortality [34]. In the 
same year, a new type of vaccine, the split vaccine, was 
authorized in the US after several clinical studies had 
demonstrated that it was less reactogenic than whole vi-
rus vaccines, especially in the early years of life [35]. 
The seventies: genetic reassortment
Split vaccines were widely used during the pandemic 
swine influenza in 1976 and in 1977, when the H1N1 
subtype re-emerged worldwide. However, they were 
seen to be less immunogenic than whole virus vaccines 
in “primed” subjects who had never been vaccinated. In-
deed, it was shown that two vaccine doses were needed 
in order to ensure effective protection [36]. 
At the beginning of the 1970s, an important innovation 
was introduced into the production of influenza vac-
cines: the genetic reassortment of influenza virus strains; 
this technique enabled the vaccine strains to grow faster 
in embryonated hen eggs [37]. 
The first subunit vaccine was created between 1976 and 
1977. This contained only the surface antigens, hemag-
glutinin (HA) and neuraminidase (NA), which were iso-
lated by means of successive purification steps.
This innovative tool proved to be highly immunogenic 
and well tolerated in humans, especially in children, al-
though two doses were needed to guarantee vaccine ef-
fectiveness during epidemics [38].
The eighties: subunit vaccines
In 1980, the first subunit vaccines were licensed in the 
United Kingdom and are currently available in several 
countries worldwide.
In 1978, as a result of a major mutation, a new virus 
strain, H1N1, appeared on the global epidemiological 
scene. This strain, which was similar to a virus circulat-
ing in 1958, emerged in Russia and began to co-circu-
late, either simultaneously or alternately, with the previ-
ous one [39]. 
Antigenic drift, caused by frequent changes in the com-
position of the virus, determined the need to update the 
vaccine composition each year. This necessity prompted 
both the implementation of the first surveillance systems 
and the production of the first trivalent vaccine, which 
included three formulation strains (one strain of influ-
enza A/ H1N1, an influenza virus A /H3N2 and a type B 
virus), in order to ensure effective protection during the 
1978 pandemic.
Live attenuated influenza vaccines
In the period 1935-1941, the first clinical trials involv-
ing live attenuated influenza vaccines were conducted. 
The efficacy of these seasonal vaccines was guaranteed 
by the correspondence between the circulating strain and 
the strain contained in the vaccine and by the virus dose 
grown in hen egg embryos [34]. 
In 1944, Stanley described in detail the preparation and 
properties of an influenza virus vaccine produced in em-
bryonated hen eggs; this vaccine was concentrated and 
purified by means of differential centrifugation and inac-
tivated by means of various procedures [23]. 
In 1949, an important change in vaccine development 
involved the introduction of the use of cell cultures for 
virus growth.
In 1997,the so-called “avian flu” pandemic broke out 
in Hong Kong. This was caused by influenza virus A/
H5N1, a highly pathogenic strain.
In order to contain this pandemic, the techniques of ge-
netic rearrangement developed in those years enabled a 
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huge number of vaccine doses to be produced in a short 
time by applying recombinant DNA technology to the 
influenza A/H5N1 virus [34]. 
Recent years
In recent years, scientific research developed new tech-
niques of immunization, which may be more immuno-
genic and better tolerated during administration, thereby 
reducing adverse events. In 2003, for instance, the FDA 
in the United States authorized the use of an intranasally 
administered live attenuated vaccine, called FluMist®, in 
adults [40]. In the 2003-2004 influenza season, an out-
break in Asia was caused by an influenza A/H5N1 strain. 
This was later used to produce a vaccine, which was li-
censed in the United States by the FDA in 2007.
More recent years saw the development of adjuvanted 
vaccines, such as those containing alum adjuvants and 
the oil in water adjuvant MF-59, which significantly en-
hanced antigenicity [6].
Specifically, MF-59-adjuvanted vaccines were used in the 
elderly and in young children, and proved to elicit a good 
response even to pandemic strains with which subjects had 
not been primed by natural influenza infection. Similar re-
sponses were obtained through the use of other emulsions, 
such as stable emulsion (SE) and AS03, which were includ-
ed in the 2009 pandemic influenza vaccines [36]. 
In the most recent pandemic season (2009), the influ-
enza virus H1N1, which was transmitted to humans by 
pigs, was estimated to have caused more than 200,000 
deaths in the first 12 months of its circulation [41]. 
A massive effort to produce vaccine for the new H1N1 
strain began shortly after scientists identified the virus. 
The virus proved to grow slowly during the manufac-
turing process, which relies on cultivation of the virus 
in chicken eggs. Because of manufacturing delay, the 
vaccine was available in most countries after the second 
peak of influenza cases at the end of October leaving 
most people not immunized while influenza H1N1 virus 
was circulating [42]. 
In the elderly, the vaccine efficacy normally decreases, be-
cause of immunosenescence. For this reason, in 2009 the 
Advisory Committee on Immunization Practices (ACIP) 
recommended and authorized the use of high-dose Flu-
zone®, a new formulation containing a 4-fold higher HA 
dose than the traditional trivalent vaccine [43].
In 2011, as a result of developments in research into 
new vaccine delivery techniques, the FDA first autho-
rized the intradermal administration of Fluzone®. This 
new route of administration involved antigen-presenting 
cells (APCs) in the dermis; these cells process antigens 
for subsequent presentation in the lymphoid organs, re-
sulting in the stimulation of both innate and adaptive 
immunity. The intradermal vaccines elicited a better im-
munological response than intramuscular vaccines, par-
ticularly in the elderly; in healthy adults, it yielded an 
immune response comparable to that elicited by the tra-
ditional vaccines, while saving on the HA dose [44-48].
In 2012, the FDA approved Fluarix®, the first quadri-
valent vaccine in the United States. This split vaccine 
contained two influenza A strains and two influenza 
B antigens. The presence of an additional influenza B 
strain reduced the possibility of a mismatch between the 
circulating viruses and the vaccine composition, while 
maintaining the same immunogenicity and safety as 
standard trivalent vaccines [49]. 
In 2013, the FDA approved FluBlock®, a recombinant 
trivalent influenza vaccine, for use in people aged be-
tween 18 and 49 years. FluBlock® was licensed in a 
spray formulation and was the first trivalent influenza 
vaccine made by using recombinant DNA technology. 
Derived from Baculovirus, it contained a 3-fold higher 
HA dose than traditional trivalent vaccines [50, 51]. The 
scale-up potential of the insect cell/baculovirus vector 
system may offer advantages in terms of rapid antigen 
change and response to a pandemic situation [31]. 
Currently, scientists are exploring the fascinating prospect of 
developing a universal vaccine by exploiting T-cells and by 
attempting to elicit broadly neutralizing antibodies. Moreo-
ver, efforts are being made to design M2e- or stalk-based 
vaccines, since these proteins (the type-2 matrix protein and 
the stalk domain of HA, respectively) are quite well con-
served from an evolutionary standpoint [52, 53].
Conclusions
In the hundred years since the influenza virus was iso-
lated, influenza vaccine preparations have evolved to 
ensure effective protection, while maintaining a good 
safety and tolerability profile.
The recurring mutations of influenza strains prompted 
the introduction of a quadrivalent inactivated vaccine, 
the composition of which is determined on the basis of 
the most frequent strains isolated in the previous season 
during continuous surveillance by the WHO.
Current research priorities include the development of 
a universal influenza vaccine that could offer protection 
against all influenza virus strains, thereby overcoming 
the challenges faced due to antigenic drift and shift or of 
co-circulation of different viral strains. Another important 
priority is to identify sustainable vaccine production plat-
forms capable of rapidly meeting the large global demands 
for influenza vaccine in the face of an influenza pandemic.
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